| 邹娇,佟长青.CPX-351治疗急性髓系白血病的研究进展[J].安徽医药,2026,30(5):896-901. |
| CPX-351治疗急性髓系白血病的研究进展 |
| Research progress on CPX-351 in the treatment of acute myeloid leukemia |
| |
| DOI：10.3969/j.issn.1009-6469.2026.05.010 |
| 中文关键词: 急性髓系白血病 柔红霉素 阿糖胞苷 脂质体包载 真实世界研究 |
| 英文关键词: Acute myeloid leukemia Daunorubicin Cytarabine Liposome entrapment Real-world research |
| 基金项目: |
|
| 摘要点击次数: 258 |
| 全文下载次数: 71 |
| 中文摘要: |
| 近年来，随着各种靶向药物、免疫调节剂等药物的出现，急性髓系白血病( AML)的缓解率逐渐升高，但继发性 AML(sAML)的预后仍旧很差。 sAML主要分为治疗相关性 AML(t-AML)和伴有骨髓增生异常相关改变的 AML(AML-MRC)。 CPX-351(也称为 Vyxeos)是柔红霉素和阿糖胞苷按 1∶5摩尔比协同包封的双药脂质体，在 AML的治疗中疗效显著，于 2017年 8月在美国(年龄 ≥1岁的病人)、 2018年 12月在欧盟和英国(所有年龄的成年人)首次获批用于初诊 t-AML或 AML-MRC的治疗。该综述主要围绕 CPX-351的作用机制、临床研究、真实世界研究、药物不良反应等方面的最新研究进行阐述。 |
| 英文摘要: |
| In recent years,with the emergence of various targeted drugs, immunomodulators and other drugs, the remission rate of AMLhas gradually increased,but the prognosis of secondary AML (sAML) is still very poor.SAML is mainly divided into therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC) with myelodysplasia-related changes. CPX-351 (also known as Vyxeos),a two-agent liposomal inclusion of daunorubicin and cytarabine in synergistic 1:5 molar ratio, is highly effective in the treat.ment of AML and is first approved for the treatment of na.ve t-AML or AML-MRC in the United States in August 2017(patients aged ≥1years) and in the European Union and the United Kingdom(adults of all ages) in December 2018.This article mainly focuses on the lat.est research on the mechanism of action of CPX-351,clinical research, real-world research,adverse drug reactions and other aspects. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
